CoChat

Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort

Mirani, Marco, Favacchio, Giuseppe, Serone, Eliseo, Lucisano, Giuseppe, Rossi, Maria Chiara, Berra, Cesare C. · 2018 · Pharmacological Research
Cited by 31

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

&NA; In the last years, due to new regulatory guidelines requiring a stringent documentation of cardiovascular (CV) safety of novel drugs for type 2 diabetes, cardiovascular outcomes safety trials (CVOTs) are requested. CVOTs increase the knowledge about the safety profile of the new drugs, but they have intrinsic limits that make difficult their transferability to clinical practice. For this reason, real world evidence is considered an important complement to experimental data. Among the glucagon‐like peptide‐1 receptor agonists, liraglutide in the LEADER CVOT demonstrated superiority in reducing the risk of major CV events (MACEs) vs. placebo. We conducted an observational, retrospective, longitudinal study based on 307 patients with T2DM treated with liraglutide under routine clinical practice conditions. Real world impact of liraglutide on metabolic control, CV risk factors, hypoglycemia and CV events was assessed. Improvements during 36 months were found in HbA1c (–1.0%; p < 0.0001), fasting blood glucose (–17.6 mg/dL; p < 0.0001), body weight (–3.2 kg; p < 0.0001), waist circumference (‐1.45 cm; p = 0.004), systolic blood pressure (‐10.41 mmHg; p < 0.0001), diastolic blood pressure (‐3.69 mmHg; p < 0.0001), total cholesterol (–7.96 mg/dL; p =0.008) and triglycerides (‐20.60 mg/dl; p = 0.01). No severe hypoglycemia occurred. Incidence of MACEs in this cohort was lower than in the LEADER study (2.59 vs. 3.4 events per 100 person‐years), confirming CV safety of liraglutide even in the real world. On the other hand, a higher incidence of CV event in patients with established CV disease was documented (8.1 events per 100 person‐years), in spite of the use of liraglutide. In conclusion, 36‐month durability and CV safety of liraglutide were documented in a real world cohort of T2DM patients, with sustained benefits on a large array of CV risk factors. Graphical abstract Figure. No caption available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2018.09.003

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 31

Metadata

Authors
Mirani, M., Favacchio, G., Serone, E., Lucisano, G., Rossi, M. C., & Berra, C. C.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2018-11
Volume
137
Pages
270-279
ISSN
1043-6618 (ISSN-L)
OpenAlex
W2891475047
Cited by
31
References
12
FWCI
1.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.